MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.05 USD
-0.05 (-1.61%)
Updated Apr 26, 2024 03:44 PM ET
After-Market: $3.08 +0.03 (0.98%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Brokerage Reports
0 items in cart
MEI Pharma, Inc. [MEIP]
Reports for Purchase
Showing records 61 - 80 ( 141 total )
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Positive Data Update for Pracinostat in Frontline AML Elderly Patients, Looking Ahead to Unblinding of Untreated MDS Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Improving Responses and Signs of Durability Frontline AML Study
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Fiscal 2Q15 Earnings; Recommend Buying on Weakness Ahead of March MDS Unblinding; Reiterate OUTPERFORM Rating and $12 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
F2Q15 Results; Data Card Turned Over Next Month
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Reaches Response Milestone in Phase II - Clinical Trial of Pracinostat in Refractory Myelodysplastic Syndrome
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Reaches Response Milestone in Phase II Clinical Trial of Pracinostat in Refractory Myelodysplastic Syndrome
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Clinical Milestone Achieved in r/rMDS Is Promising For Front-Line Study
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Busy 2015 Ahead, Is Pracinostat Priced In? Removing from Focus List
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
KOL Event Drives Pracinostat Buzz; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MEIP Presents Positive Updated Interim Data from Phase II Study of Pracinostat and Vidaza in Elderly Patients Previously Untreated with AML
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Like a Fine Wine, Responses Improve with Time; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J